<DOC>
	<DOC>NCT02970305</DOC>
	<brief_summary>To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of the negative symptoms of schizophrenia</brief_summary>
	<brief_title>Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Pimavanserin</mesh_term>
	<criteria>1. Adults patients, aged 18 years and above 2. A clinical diagnosis of schizophrenia with a minimum duration of 1 year 3. Has predominant negative symptoms according to predefined study criteria 4. Has had equal to or less than 10 years of treatment with an antipsychotic 5. The main background antipsychotic with which the subject is being treated must be one of the antipsychotics listed below: Aripiprazole Risperidone Olanzapine Lurasidone Cariprazine Brexpiprazole Asenapine Risperidone longacting injection Aripiprazole longacting injectables: Abilify Maintena® Aristada® 1. Patient has a psychiatric disorder other than schizophrenia 2. Patient has current evidence of a serious and/or unstable neurologic, cardiovascular, respiratory, gastrointestinal, renal, hepatic, hematologic, or other medical disorder, including cancer or malignancies, which would affect the patient's ability to participate in the program 3. Patient has had a myocardial infarction in the last six months 4. Patient has a history or symptoms of long QT syndrome Patients will be evaluated at screening to ensure that all criteria for study participation are met. Patients may be excluded from the study based on these assessments (and specifically if it is determined that their baseline health and psychiatric condition do not meet all prespecified entry criteria).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>